It s time to join the conversation about the future of cancer care.

Transcription

1 It s time to join the conversation about the future of cancer care. September 16 18, 2016 Boston CJCP The official meeting of the Journal of Clinical Pathways

2 A new conference focused on the expansion of clinical pathways and their increasing influence on patient care. Data are critical to the evolution of cancer care delivery. With $137 billion spent on treatment in the U.S. annually, cancer care delivery is increasingly being scrutinized in an attempt to find new strategies that reduce costs and variability, drive value, and provide optimal care. Tools including clinical pathways have been introduced, but they raise new questions about patient access, care quality, and transparency. For three days in September, the most important discussions on transforming cancer care delivery will take place in Boston. Payers, providers, and clinical pathway developers will gather for a new meeting, one that aims to bring stakeholders throughout the oncology care spectrum together to address critical questions around clinical pathways and develop new strategies for addressing evidence-based care. Brought to you by the Journal of Clinical Pathways, the Clinical Pathways Congress will help you aggregate lessons and ideas from those involved in pathway development and implementation. Engage in the discovery of new solutions to ensure clinical pathways are designed to align with provider, payer and patient needs. It s time you joined the conversation. Register Today clinicalpathwayscongress.com 2 clinicalpathwayscongress.com

3 Clinical Pathways Congress is designed for Directors of oncology practices, programs and cancer centers ACO oncologists Pathway development executives Reimbursement and HEOR specialists The program will cover the opportunities and challenges associated with the adoption of clinical pathways: Design & Testing Practice managers/ administrators Managed care executives Other stakeholders, such as advanced practice nurses, pharmacists and medical directors, who are in a position to influence clinical pathway development. Implementation & Measurement Impact on quality of care, costs and health outcomes Connect with a community of multidisciplinary stakeholders involved with clinical pathways. Gain insight into pathway design, testing, implementation, standards, and measurement. Ask critical questions and foster discussion about pathways and their impact on patient experience, outcomes, and expenditures. JCP About Journal of Clinical Pathways The mission of Journal of Clinical Pathways is to provide a platform for original research, insights, and perspectives in the pursuit of attaining quantifiable value in healthcare. Published monthly, the journal features peer-reviewed educational and informational articles on topics including comparative-effectiveness research; big data analytics; methods in clinical pathway development; optimizing clinical pathway implementation, compliance, and adherence; evaluating health, economic, and patient-centered outcomes; and alternative payment and value-based care models. clinicalpathwayscongress.com

4 Meet the Steering Committee The Faculty Alan Balch PhD Bruce Feinberg DO Richard L. Schilsky, FACP, FASCO Robin T. Zon, FACP, FASCO Chair, ASCO Pathways Task Force Vice President, Finance & Quality Chair Michiana Hematology-Oncology, PC Dwight E. Heron, MBA, FACRO, FACR Professor and Vice Chairman of Clinical Affairs, Department of Radiation Oncology University of Pittsburgh School of Medicine/University of Pittsburgh Cancer Institute/UPMC CancerCenter Chairman, Department of Radiation Oncology UPMC Shadyside Medical Director Via Oncology Bruce Feinberg DO Vice President Clinical Affairs, Chief Medical Officer Cardinal Health Specialty Solutions Winston Wong PharmD President W-Squared Group Michael Kolodziej National Medical Director for Oncology Strategy Aetna Chief Executive Officer Patient Advocate Foundation Hampton, Virginia Alex Bastian MBA Vice President Gfk Market Access San Francisco, California Sushil Beriwal Clinical Associate Professor University of Pittsburgh School of Medicine Deputy Director of Radiation Services, UPMC CancerCenter Residency Program Director, Radiation Oncology Medical Director, Department of Radiation Oncology, Magee-Women s Hospital of UPMC Director, Brachytherapy University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Graham Burks Product Market Lead Fuse by Cardinal Health Memphis, Tennessee Atul Dhir, DPhil Chief Executive Officer New Century Health Wellesley, Massachusetts Peter Ellis Clinical Professor of Medicine University of Pittsburgh School of Medicine Deputy Director, Clinical Services; Associate Chief Medical Officer UPMC CancerCenter Pittsburgh, Pennsylvania Vice President, Clinical Affairs Chief Medical Officer Cardinal Health Specialty Solutions Dwight E. Heron, MBA, FACRO, FACR Professor and Vice Chairman of Clinical Affairs, Department of Radiation Oncology University of Pittsburgh School of Medicine/University of Pittsburgh Cancer Institute/ UPMC CancerCenter Chairman, Department of Radiation Oncology UPMC Shadyside Medical Director Via Oncology Jim Koeller MS Professor University of Texas at Austin The Health Science Center, San Antonio San Antonio, Texas Michael Kolodziej National Medical Director for Oncology Strategy Aetna Marcus Neubauer Medical Director, Oncology Solutions McKesson Specialty Health Seattle, Washington Ray Page DO, PhD, FACOI President & Director of Research The Center for Cancer and Blood Disorders Fort Worth, Texas Senior Vice President and Chief Medical Officer American Society of Clinical Oncology Alexandria, Virginia Edward J. Stepanski PhD Chief Operating Officer, Vector Oncology Professor of Medicine University of Tennessee Health Sciences Center Memphis, Tennessee Winston Wong PharmD President W-Squared Group Robin T. Zon, FACP, FASCO Chair, ASCO Pathways Task Force Vice President, Finance & Quality Chair Michiana Hematology-Oncology, PC We are trying to attain the best possible outcomes at a fair cost. Pathways represent the logical first step in this process. Michael Kolodziej Steering Committee Member 6 clinicalpathwayscongress.com

5 The Agenda Three days that will change how you think about evidence-based cancer care Saturday September 17 Registration and Breakfast in the Exhibit Hall 6:50 a.m. 7:50 a.m. Opening Remarks 8:00 a.m. 8:10 a.m. Friday September 16 Opening Remarks 5:20 p.m. 5:30 p.m. Keynote Presentation 5:30 p.m. 6:30 p.m. Registration 3:00 p.m. 8:10 p.m. Welcome Reception 4:40 p.m. 5:10 p.m. complimentary refreshments for all attendees. Precision Medicine: An Essential Component of Oncology Clinical Pathways Precision medicine seeks to deliver the right treatment to the right patient at the right time. Given the great heterogeneity of both patients and tumors, realizing the goals of precision medicine for cancer treatment requires that each patient receive a treatment tailored to his or her unique tumor biology, clinical circumstances, and goals. Clinical pathways seek to minimize variations in care by guiding physicians to treatments supported by high-level evidence supplemented, in some cases, with expert medical opinion. Pathways focus on optimal approaches to groups of similar patients. Dr. Schilsky will focus on the tension inherent in these two approaches to cancer care and describe how precision medicine strategies can be integrated in clinical pathways to support high-value cancer care. Faculty: Richard L. Schilsky,, FACP, FASCO Exhibit Hall Grand Opening Reception 6:40 p.m. 8:10 p.m. complimentary refreshments for all attendees. A cookie cutter approach to cancer care will impede our ability to personalize care and meet patient needs. Pathways need to demonstrate flexibility to capitalize on advances in medical treatment, reflect development with scientific evidence, and assure providers that they offer the best possible outcomes for the patient. Robin T. Zon, FACP, FASCO Steering Committee Member Clinical Pathways: From Utilization Management to Their Present (and Future) Role in Shaping Value-Based Care 8:10 a.m. 8:40 a.m. Physician adoption and implementation of evidence-based medicine is critical to high-quality care. In oncology, physician prescribing of chemotherapy has been an initial focus of the effort to deploy and measure physician performance in the world of evidence-based medicine. This is in part related to the ever-increasing cost of chemotherapy. Clinical pathways provide a structured process for evidence review, implementation at point of care, and measurement to permit quality improvement. In this session, Dr. Kolodziej will review the genesis of cancer clinical pathways, current state of affairs, and impact to date. Faculty: Michael Kolodziej, ASCO s Clinical Pathways Policy Statement with Comments from a Multidisciplinary Panel 8:50 a.m. 9:50 a.m. Under ideal circumstances, clinical pathways are detailed, evidencebased treatment protocols for delivering quality cancer care for patients with specific disease types and stages. However, the recent proliferation of these treatment management tools in cancer care has raised significant concerns about patient access, care quality, and transparency in pathway development and implementation. The ASCO Task Force on Clinical Pathways developed and released a policy statement to help guide the future development and implementation of clinical pathways in oncology, and ensure that all patients with cancer have access to high-quality care. Faculty: Atul Dhir,, D.Phil; Michael Kolodziej, ; Robin T. Zon,, FACP, FASCO clinicalpathwayscongress.com

6 Agenda Saturday September 17 Continued The success of clinical pathway programs proves that when payers and providers work together, they can drive innovations that benefit all players in the care continuum, including the patient. Bruce Feinberg do Steering Committee Member Clinical Pathways: A Point- Counterpoint from the Provider and Payer Perspective 10:00 a.m. 11:00 a.m. Explore variations in the development and maintenance process of provider and payer clinical pathway programs as Dr. Page and Dr. Wong share their viewpoints on who should control the choice and development of pathways, interest in clinical pathways as a means to help control cost, and opportunities for provider and payer collaboration. Will our goals align, or will we agree to disagree? Faculty: Ray Page, DO, PhD, FACOI; Winston Wong, PharmD Case Presentation: Designing a Colorectal Cancer Pathway 11:10 a.m. 12:10 P.m. Lunch Innovation Theater 12:20 p.m. 1:35 p.m. (non-accredited) complimentary lunch. seating is limited. Can Physician Behavior Change? The Case for Provider-Driven Pathways 1:45 p.m. 2:45 p.m. Clinical pathways are an important clinical and administrative tool that has been shown to foster consistent, state-of-the-art quality care by reducing variability and potentially controlling excess cost. Drs. Beriwal and Heron will present the evolution of a comprehensive peer review, provider-driven clinical pathways process that has resulted in significant improvement in quality, and consistent application of current treatment guidelines in one of the United States largest integrated radiation oncology networks, consisting of 21 radiation oncology sites. Faculty: Sushil Beriwal, ; Dwight E. Heron,, MBA, FACRO, FACR From 2010 to 2012, CardinalHealth and CareFirst BlueCross Blue Shield oncology pathways demonstrated: $8,000,000 in cost savings 15% decrease in cancer-related costs 7% decrease in patient hospital admissions Source: Nelson R. Clinical pathways program can reduce costs in oncology. Medscape. Published August 7, Case Presentation: Designing a Lung Cancer Pathway 2:55 p.m. 3:55 p.m. How Should Medication Cost Be Factored into Value-Based Care? 4:00 p.m. 5:00 p.m. By definition, value-based care incorporates medication cost into clinical decision making. However, robust debate continues as to who is responsible for managing drug cost, how cost should be communicated to the multiple stakeholders, and even what constitutes medication cost, since a different cost and value may be attributed to the same medication depending on the particular indication. Mr. Bastian and Dr. Feinberg will illustrate the complexities inherent in assessing drug cost as we migrate to value-based care. Faculty: Alex Bastian, MBA; Bruce Feinberg, DO (non-accredited) Health Information Technology: Software Solutions for Clinical Pathways 5:10 p.m. 6:10 p.m. Numerous clinical pathways programs are now being deployed. Although many require the same clinical elements and offer the same therapeutic choices, this variability has created a large administrative burden for oncology practices. One solution is integration of content directly in to the EMR. Another solution is a north of EMR software that can be imbedded in any/ all EMR. Mr. Burks and Dr. Neubauer will explore two possible solutions and discuss how integration and utilization can lead to improved clinician work flow. Faculty: Graham Burks; Marcus Neubauer, Exhibit Hall Reception 6:20 p.m. 7:50 p.m. complimentary refreshments for all attendees. 10 clinicalpathwayscongress.com

7 Agenda Sunday September 18 Opportunities for Visibility A limited number of exhibit booths and sponsorships are available for the Clinical Pathways Congress. For more information on ways to reach this exclusive audience of oncology care leaders, please contact: Jeff Hennessy National Account Manager jhennessyjr@hmpcommunications.com Continental Breakfast 6:50 a.m. 7:20 a.m. Real-World Outcomes from Oncology Clinical Pathway Programs: Case Examples from a Payer Perspective 7:30 a.m. 8:30 a.m. Clinical pathways are viewed as valuable practice tools leading to presumed cost savings. Can broadly implemented clinical pathways achieve reasonable physician compliance, resulting in cost savings? Professor Koeller will review studies evaluating oncology clinical pathways programs, and will provide an overview on the benefits and cost savings of implementing an oncology clinical pathway. Faculty: Jim Koeller, MS Case Presentation: Designing a Chronic Lymphocytic Leukemia (CLL) Pathway 8:40 a.m. 9:40 a.m. Patient Impact on the Implementation and Effectiveness of Clinical Pathways 9:50 a.m. 10:50 a.m. Clinical pathways can profoundly affect the patient experience by transforming the care delivery process. Dwight E. Heron, MBA, FACRO, FACR Steering Committee Member Brunch Innovation Theater 11:00 a.m. 12:15 p.m. (non-accredited) complimentary brunch. seating is limited. More than Medication: A 360 View of the Optimal Design and Utilization of Clinical Pathways 12:25 p.m. 1:25 p.m. Pathways are more than a drug decision support tool. They should facilitate quality care in all aspects of the patient interaction to include evaluation, treatment, education, palliative care and end of life. In this session, Dr. Ellis will discuss means with which these are being addressed in at least one of the pathways programs. Faculty: Peter G. Ellis, Tackling the Hot-Button Issues Around Clinical Pathways: A Rapid-Fire Session 1:35 p.m. 2:35 p.m. Clinical Pathways Congress Steering Committee members share insight and perspective on current and emerging hot-button topics surrounding clinical pathway design, implementation and impact. Closing Remarks 2:35 p.m. 2:45 p.m. Oncology clinical pathways are an important component of comprehensive programs that aim to contain the cost of care while maintaining or improving the quality of care. Understanding patient preference is key to personalizing care and optimizing the patient experience. Dr. Balch and Dr. Stepanski will explore advances in patient reported outcome tools, progress in directing patient experience to physicians at the point of care, and integration of patient experience into clinical pathways to make them more impactful on shared decision making. Faculty: Alan Balch, PhD; Edward J. Stepanski, PhD Accreditation Information Activity Overview The Clinical Pathways Congress will occur on September 16 18, 2016 at the Westin Waterfront Boston. A question-and-answer session with the faculty will follow each presentation. To be eligible for documentation of credit, participants must complete the online evaluation form at www. naccme.com. All individuals who participate in the conference and submit the completed evaluation form online may immediately print their documentation of credit. For questions regarding this educational activity, please call See the registration rates section of the website for fee information. Cancellation Policy Please note the cutoff date for cancellation is August 8, All cancellations must be received in writing and postmarked by that date. Full registration (less a $100 processing fee or full registration amount, whichever is less) will be refunded only to cancellations received in writing before the above date. No refunds will be issued after August 8, 2016 without exception. Registrations are transferrable at any time. Learning Objectives After attending the Clinical Pathways Congress 2016 meeting, participants should be able to: Outline the opportunities and challenges associated with using clinical pathways as a foundation for value-based care Examine the roles and responsibilities of payers, providers, and pathway developers in creating and implementing clinical pathways Contribute to the effective implementation of clinical pathways to optimize quality of care, cost efficiency, and health outcomes Intended Learners This activity is designed for directors of oncology practice programs and cancer centers, oncologists, hematologists, commercial and government payers, pathway development executives, reimbursement specialists, specialty pharmacists, HEOR specialists and other healthcare professionals interested in learning how to implement, integrate, and measure treatment pathways. Accreditation North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. *CME/CNE/CPE credit hours subject to change CME NACCME designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CNE This continuing nursing education activity awards 12.5 contact hours. Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.5 contact hours. CPE Each of these activities is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN L01-P, L01-P, L01-P, L01-P, L01-P, L01-P, L01-P, L01-P, L01-P, L01-P, L01-P, L01-P). This activity is approved for.50 contact hours (0.05 CEU) of continuing pharmacy education ( L01-P). Each of these educational activities is a knowledge-based activity. ACPE Credit Policy Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period. ADA Statement North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call Provided by North American Center for Continuing Medical Education, LLC, an HMP Communications Holdings Company. clinicalpathwayscongress.com

8 B O S T O N Registration Form First Name last Name S suffix/credentials Title Company/Organization/Practice Name Department Address City State zip Country phone FAx npi/license Professional Category DO NP PA MSN/BN/RN Pharmacist Administrator Industry Consultant None Other Specialty Oncology Oncology/Hematology Other Hotel & Travel Profession Pathway Development Professional Cancer Treatment Center Professional Reimbursement Specialist/Oncology Practice Manager ACO Oncologist ACO Oncologist/Hematologist Commercial/Medicare MCO Payer (HMO/PPO/PBM/IDN) Government Payer (Medicaid/VA/DoD/Prisons) Group Purchasing Organization Professional Other In which care setting is the majority of your time spent? Hospital Office-based Cancer clinic/center Research None Other Are you currently using clinical pathways in your practice or organization? Yes No Official Clinical Pathways Congress Hotel The Westin Boston Waterfront 425 Summer Street Boston, MA Special Conference Rate: $299 To make hotel reservations and for travel information, please visit clinicalpathwayscongress.com/hotel-travel The deadline to reserve a room at the discounted rate is August 8, Early Bird Rate February 22 May 9 $495 Advance Rate May 10 June 27 $595 Standard Rate June 28 August 29 $695 Method of Payment (Please choose from the following options) Check made payable to HMP Communications. All checks must be drawn on a U.S. bank in U.S. funds. In memo line, please note, Registration for Clinical Pathways Congress. Mail to HMP Communications: 70 E. Swedesford Road, Suite 100, Malvern, PA MasterCard Visa Discover American Express Name on CARD Onsite Rate August 30 September 18 $750 Resident/Postdoctorate/ Fellow $95 standard rate $125 onsite rate Total Payment Enclosed $ Credit Card Number 3 Ways to Register Online clinicalpathwayscongress.com Call Mail your registration form with payment to: HMP Communications 70 East Swedesford Road, Suite 100 Malvern, PA Expiration Date S security Code Billing Postal Code Signature of the Cardholder ( required ) 14 clinicalpathwayscongress.com Cancellation Policy If your registration must be cancelled, the course fee (less $100 in administrative costs) will be refunded if we are notified in writing by Monday, August 8, After August 8, 2016 no refunds will be given. There are no exceptions to these policies. Payments made may not be applied toward tuition for future Clinical Pathways Congresses, or other meetings or products offered by NACCME.

9 70 E. Swedesford Road Suite 100 Malvern, PA September 16 18, 2016 The Westin Boston Waterfront Boston, MA A new conference focused on the expansion of clinical pathways and their increasing influence on patient care. Register Today clinicalpathwayscongress.com It s time to join the conversation about the future of cancer care. September 16 18, 2016 Boston C JCP The official meeting of the Journal of Clinical Pathways